Associations - CCND1 (Cyclin D1)

CCND1 amplification	Melanoma	CCND1 amplification	Melanoma	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B
CCND1 overexpression	Mantle Cell Lymphoma	CCND1 overexpression	Mantle Cell Lymphoma	INCB50465 Sensitive: C2 – Inclusion Criteria INCB50465 Sensitive : C2	INCB50465 Sensitive: C2 – Inclusion Criteria INCB50465 Sensitive : C2
CCND1 expression	Non Small Cell Lung Cancer	CCND1 expression	Non Small Cell Lung Cancer	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
CCND1 underexpression	Melanoma	CCND1 underexpression	Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
CCND1-H	Breast Cancer	CCND1-H	Breast Cancer	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3
CCND1 P241P	Colorectal Cancer	CCND1 P241P	Colorectal Cancer	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
CCND1 overexpression	Breast Cancer	CCND1 overexpression	Breast Cancer	AMG 386 Resistant: C3 – Early Trials AMG 386 Resistant : C3	AMG 386 Resistant: C3 – Early Trials AMG 386 Resistant : C3
CCND1 overexpression	Breast Cancer	CCND1 overexpression	Breast Cancer	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3	ABT-888 Resistant: C3 – Early Trials ABT-888 Resistant : C3
CCND1 amplification	Estrogen Receptor Positive Breast Cancer	CCND1 amplification	Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CCND1 amplification	Solid Tumor	CCND1 amplification	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CCND1 amplification	Breast Cancer	CCND1 amplification	Breast Cancer	Aromatase inhibitor Resistant: C3 – Early Trials Aromatase inhibitor Resistant : C3	Aromatase inhibitor Resistant: C3 – Early Trials Aromatase inhibitor Resistant : C3
CCND1 overexpression	Multiple Myeloma	CCND1 overexpression	Multiple Myeloma	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3
CCND1 amplification	Melanoma	CCND1 amplification	Melanoma	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3
CCND1 overexpression	Estrogen Receptor Positive Breast Cancer	CCND1 overexpression	Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3	tamoxifen Resistant: C3 – Early Trials tamoxifen Resistant : C3
CCND1 amplification	Lung Non-Small Cell Squamous Cancer	CCND1 amplification	Lung Non-Small Cell Squamous Cancer	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CCND1 mutation + HR positive	HER2 Negative Breast Cancer	CCND1 mutation + HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CCND1 amplification	Melanoma	CCND1 amplification	Melanoma	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
CCND1 overexpression	Squamous Cell Skin Cancer	CCND1 overexpression	Squamous Cell Skin Cancer	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
CCND1 amplification	Head and Neck Cancer	CCND1 amplification	Head and Neck Cancer	cetuximab + palbociclib Sensitive: C3 – Early Trials cetuximab + palbociclib Sensitive : C3	cetuximab + palbociclib Sensitive: C3 – Early Trials cetuximab + palbociclib Sensitive : C3
CCND1 expression	Diffuse Large B Cell Lymphoma	CCND1 expression	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
HR positive + CCND1 amplification	HER2 Negative Breast Cancer	HR positive + CCND1 amplification	HER2 Negative Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
EGFR mutation + CCND1 expression + CDKN2A deletion	Non Small Cell Lung Cancer	EGFR mutation + CCND1 expression + CDKN2A deletion	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
ER positive + ESR1 mutation + CCND1 amplification	HER2 Negative Breast Cancer	ER positive + ESR1 mutation + CCND1 amplification	HER2 Negative Breast Cancer	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
ALK positive + MYC amplification + CCND1 deletion	Non Small Cell Lung Cancer	ALK positive + MYC amplification + CCND1 deletion	Non Small Cell Lung Cancer	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
ER L536H + ER D538G + CCND1 amplification	Breast Cancer	ER L536H + ER D538G + CCND1 amplification	Breast Cancer	palbociclib Sensitive: C4 – Case Studies palbociclib Sensitive : C4	palbociclib Sensitive: C4 – Case Studies palbociclib Sensitive : C4
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion	Non Small Cell Lung Cancer	ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion	Non Small Cell Lung Cancer	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
BCL2 overexpression + CCND1 overexpression	Multiple Myeloma	BCL2 overexpression + CCND1 overexpression	Multiple Myeloma	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4
CCND1 amplification	Squamous Cell Carcinoma of Head and Neck	CCND1 amplification	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: C4 – Case Studies cetuximab Sensitive : C4	cetuximab Sensitive: C4 – Case Studies cetuximab Sensitive : C4
CCND1 overexpression	Ependymoma	CCND1 overexpression	Ependymoma	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D	abemaciclib Sensitive: D – Preclinical abemaciclib Sensitive : D
CCND1 expression	Mantle Cell Lymphoma	CCND1 expression	Mantle Cell Lymphoma	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
AR underexpression + IL1R1 underexpression + CCND1 overexpression	Acute Myelogenous Leukemia	AR underexpression + IL1R1 underexpression + CCND1 overexpression	Acute Myelogenous Leukemia	venetoclax + ABBV-744 Sensitive: D – Preclinical venetoclax + ABBV-744 Sensitive : D	venetoclax + ABBV-744 Sensitive: D – Preclinical venetoclax + ABBV-744 Sensitive : D
CCND1 expression + CDK4 expression	Mantle Cell Lymphoma	CCND1 expression + CDK4 expression	Mantle Cell Lymphoma	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D

CCND1 (Cyclin D1)

Associations(36)

Associations
(36)